Advanced Cancer Clinical Trial
Official title:
A Phase I Trial of Docetaxel and Sirolimus in Patients With Advanced Malignancies
The goal of this clinical research study to find the highest tolerated dose of the
combination of Taxotere (docetaxel) and Rapamycin (sirolimus) when given to patients with
advanced cancer.
Researchers also want to find highest tolerated dose of the combination of docetaxel,
sirolimus, and prednisone when given to patients with advanced prostate cancer. The safety
of both drug combinations will also be studied.
The Study Drugs:
Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die.
It is believed to be weakly effective at killing blood vessels in tumor tissue as well.
Sirolimus is designed to block a protein called mammalian target of rapamycin (mTOR) inside
the cancer cell.
Prednisone is a corticosteroid that is similar to a natural hormone made by your body.
Prednisone is often given in combination with chemotherapy to treat cancer.
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a dose
level of the combination of docetaxel and sirolimus based on when you joined this study. Up
to 12 dose levels of docetaxel and sirolimus will be tested. Three (3) to 6 participants
will be enrolled at each dose level. The first group of participants will receive the lowest
dose level. Each new group will receive a higher dose than the group before it, if no
intolerable side effects were seen. This will continue until the highest tolerable dose of
docetaxel and sirolimus is found. Once the highest tolerable dose of docetaxel and sirolimus
is found, up to 12 more patients may be enrolled to further study the safety of the drug at
each of that dose.
If you have prostate cancer, you will also receive prednisone. All participants who receive
prednisone will receive the same dose level.
Study Drug Administration:
Each study cycle is 21 days.
Everyday, you will take sirolimus by mouth 1 time a day. Sirolimus can be taken with or
without food, but should be taken at the same time everyday.
On Day 1 of every cycle, you will receive docetaxel by vein over about 1 hour.
If you are taking prednisone, you will take it 2 times every day by mouth with food and
water.
Study Visits:
Every week for the first 3 weeks and then about every 3 weeks, blood (about 5 teaspoons)
will be drawn for routine tests. You will also have a physical exam.
Every 6 weeks, women who are able to have children will have blood drawn for a pregnancy
test.
About every three weeks, blood (about 5 teaspoons) will be drawn for routine tests, to check
your kidney function, and for biomarker tests.
About every 6 weeks, you will have a CT scan and x-ray to check the status of the disease.
Length of Study:
You will be on study for as long as you are benefitting. You will be taken off the study if
the disease gets worse or you experience intolerable side effects.
Follow-Up:
If you experience intolerable side effects, you will be followed until the side effect has
resolved or the side effect does not continue to improve or get worse. The study doctor will
tell you what tests will need to be performed.
This is an investigational study. Docetaxel is FDA approved and commercially available for
the treatment of advanced cancers such as breast, lung, and prostate cancer. Sirolimus is
FDA approved and commercially available for the prevention of transplant rejection in kidney
transplant patients. Prednisone is FDA approved and commercially available for the treatment
of prostate cancer when given with docetaxel.
The combination of docetaxel and sirolimus, with or without prednisone, to treat advanced
cancer is investigational. Most patients in this study will receive docetaxel and sirolimus.
However, if you have prostate cancer, you will receive docetaxel, prednisone, and sirolimus.
Up to 68 patients will be enrolled in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
| Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |